Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 3 · below the Ichimoku cloud · RSI 25 (oversold) · MACD above its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $12.5M | 0.02% | 643.27K | +132% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MLTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 26, 2026 | Reich KristianOfficer | Sale at price 20.00 per share. | 1.1K | $22.00K |
| Jul 21, 2026 | Reich KristianOfficer | Sale at price 20.00 - 20.02 per share. | 52.4K | $1.05M |
| Jul 19, 2026 | Reich KristianOfficer | Sale at price 20.09 per share. | 43.7K | $877.93K |
| Jul 14, 2026 | Reich KristianOfficer | Sale at price 20.01 per share. | 16.1K | $322.26K |
| Jul 9, 2026 | Santos Da Silva JorgeChief Executive Officer | Sale at price 20.01 - 20.02 per share. | 102.2K | $2.05M |
| Jun 30, 2026 | Santos Da Silva JorgeChief Executive Officer | Sale at price 20.03 per share. | 47.8K | $956.93K |
| Jun 21, 2026 | Bodenstedt MatthiasChief Financial Officer | Sale at price 22.04 per share. | 39.1K | $862.21K |
| Jun 17, 2026 | Bodenstedt MatthiasChief Financial Officer | Sale at price 19.60 - 19.68 per share. | 17.9K | $351.58K |
| Jun 16, 2026 | Reich KristianOfficer | Sale at price 18.70 - 19.43 per share. | 150K | $2.85M |
| May 10, 2026 | Bodenstedt MatthiasChief Financial Officer | Sale at price 20.02 per share. | 13.7K | $273.33K |
| Apr 13, 2026 | Bodenstedt MatthiasChief Financial Officer | Sale at price 19.56 per share. | 2.4K | $47.45K |
| Apr 12, 2026 | Santos Da Silva JorgeChief Executive Officer | Sale at price 18.23 - 18.41 per share. | 150K | $2.75M |
| Apr 9, 2026 | Bodenstedt MatthiasChief Financial Officer | Sale at price 18.94 - 19.51 per share. | 87.8K | $1.66M |
| Mar 30, 2026 | Bvf Partners L PBeneficial Owner of more than 10% of a Class of Security | Sale at price 16.79 per share. | 3.75M | $62.96M |
| Jan 6, 2026 | Bodenstedt MatthiasChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 354.3K | — |
| Dec 18, 2025 | Santos Da Silva JorgeChief Executive Officer | — | 196.3K | — |
| Dec 18, 2025 | Bodenstedt MatthiasChief Financial Officer | — | 294.5K | — |
| Dec 18, 2025 | Reich KristianOfficer | — | 35.4K | — |
| Dec 8, 2025 | Santos Da Silva JorgeChief Executive Officer | Sale at price 14.49 - 15.08 per share. | 200K | $2.97M |
| Dec 8, 2025 | Reich KristianOfficer | Sale at price 14.43 - 15.08 per share. | 202.9K | $3.01M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.9 | 11.7 | 6.5 | -12.1 | 17.1 | 1.5 | -5.3 | -18.4 | -22.3 | -11.0 | −21.0% | ||
| 2025 | -15.1 | -9.2 | -6.4 | 7.7 | -7.3 | 21.0 | 6.9 | 10.5 | -87.1 | 40.9 | 35.9 | -4.0 | −75.7% |
| 2024 | -7.5 | -13.7 | 4.1 | -18.6 | -0.6 | 8.1 | -5.3 | 12.3 | 7.8 | -7.9 | 17.3 | -0.5 | −10.3% |
| 2023 | 13.8 | 60.6 | 11.5 | -0.4 | 27.7 | 87.4 | 19.2 | -5.3 | -1.0 | -9.1 | -15.2 | 37.5 | +475.1% |
| 2022 | -0.2 | 0.8 | 11.6 | -44.1 | 24.7 | -32.1 | 20.0 | 27.9 | -3.7 | 6.2 | 20.5 | 5.7 | +6.2% |
| 2021 | -3.3 | 0.0 | -7.3 | -0.9 | -1.1 | 3.5 | -4.2 | -0.4 | 0.7 | 0.5 | -0.7 | -0.4 | −13.0% |
| 2020 | 1.4 | 9.3 | +10.8% |
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Buy / hold / sell counts